Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Research analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for Bradmer Pharmaceuticals in a note issued to investors on Tuesday, February 25th. Cantor Fitzgerald analyst B. Knoblauch expects that the company will post earnings per share of $2.74 for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. Cantor Fitzgerald also issued estimates for Bradmer Pharmaceuticals’ FY2025 earnings at $3.35 EPS.
Bradmer Pharmaceuticals Price Performance
See Also
- Five stocks we like better than Bradmer Pharmaceuticals
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Buffett’s on the Sidelines – Should You Follow?
- 3 Small Caps With Big Return Potential
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- Top Biotech Stocks: Exploring Innovation Opportunities
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
